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OBJECTIVE — To evaluate day-to-day variations of insulin needs in type 2 diabetic patients
with end-stage renal disease (ESRD) on maintenance hemodialysis.
RESEARCH DESIGN AND METHODS — We developed a 24-h euglycemic clamp in
patients who received an average of 2,200 calories in a standardized three-meal and two-snack
regimen per day, adjusted to body size and sex. Intravenous insulin was adjusted every 30 min
to achieve 5.5  1.1 mmol/l glycemia over 24 h prehemodialysis, during hemodialysis session,
and24hposthemodialysisin10type2diabeticpatients,aged55.78.7yearswith11.94.5
years diabetes duration, undergoing maintenance hemodialysis for 2.3  2.3 years. Insulin
requirements were derived from the dose of insulin administered to maintain euglycemia per
period of time and day-to-day comparisons performed.
RESULTS — Mean capillary glycemia was 5.5  0.3 mmol/l prehemodialysis and 5.3  0.2
mmol/l posthemodialysis (P  0.39). Pre- and posthemodialysis areas under the glucose curve
werecomparable.Thiswasachievedbyinfusing23.67.7IU/24hprehemodialysisvs.19.9
4.9 IU/24 h posthemodialysis, indicating a 15.3% decrease posthemodialysis (P  0.09). Basal
insulinneedsdecreasedfrom0.40.1/hprehemodialysisto0.30.1/hposthemodialysis(P
0.01). Total boluses were decreased by 2.2  3.1 IU (P  0.15). Changes in blood urea did not
correlate with changes in insulin needs (r  0.1, P  0.79).
CONCLUSIONS — The present study has demonstrated a signiﬁcant 25% reduction in
basal insulin requirements the day after dialysis compared with the day before. No signiﬁcant
change in boluses was observed, and overall the reduction of total insulin requirements was
15% equivalent to 4 IU/day posthemodialysis of marginal statistical signiﬁcance.
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D
iabetes is the most common cause
of end-stage renal disease (ESRD),
affecting at least one-third of pa-
tients starting chronic dialysis worldwide
(1). Insulin resistance is a characteristic
feature of type 2 diabetes and also of pa-
tients with chronic uremia (2–4). Insulin
resistance and reduced clearance of insu-
lin are factors that lead to swings in gly-
cemic levels, making tight glycemic
control a daunting task for diabetic pa-
tients with ESRD. In addition, hemodial-
ysis improves insulin sensitivity and also
insulinclearance,makingitmoredifﬁcult
to determine insulin requirements for pa-
tients with ESRD undergoing mainte-
nance hemodialysis and therefore
exposing them to acute metabolic inci-
dents (5,6). It is uncertain whether dialy-
sis has a potential effect on pre- to
postdialysis days’ changes in exogenous
insulin requirements. Indeed, there is
currently no evidence-based recommen-
dation for the adjustment of insulin dose
posthemodialysis in diabetic patients.
This study was undertaken to determine
the insulin requirements necessary to
achieveeuglycemiaover24hprehemodi-
alysis,duringhemodialysis,and24hpos-
themodialysis in type 2 diabetic patients
with chronic kidney disease on mainte-
nance hemodialysis.
RESEARCH DESIGN AND
METHODS— Patients were eligible
to participate if they had a conﬁrmed di-
agnosis of type 2 diabetes, had stage 5
chronic kidney disease, had given written
informed consent to participate, and had
been undergoing maintenance hemodial-
ysis for at least 3 months. Patients with
type 1 diabetes; those who had current
acute illness; those who were 10 days
from the initial visit; those taking drugs
that can modify glucose metabolism, ex-
cluding insulin and other oral antidiabe-
tes drugs; and those who were pregnant
were not eligible.
The study procedures involved an
inclusion visit and an exploration com-
prisingoneprehemodialysis,oneperhemo-
dialysis, and one posthemodialysis phase.
Inclusion visit
Within 1 week following an information
visit, patients signed informed consent
forms and were assessed for eligibility. Of
12 eligible patients who were invited, 2
refused to participate because of lack of
time. The exploration took place after ad-
justmentsoftreatmentinordertoachieve
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days prior to exploration.
Exploration
Participants were invited to arrive at the
hospital at least 24 h before their index
hemodialysis session. The exploration
started after an overnight fast of at least
8 h and 24 h before the index dialysis
session.Patientswereadmittedfor50–52
consecutive hours in three continuous
phases (pre-, per-, and posthemodialysis)
and took place at the endocrinology and
the hemodialysis units. During these ex-
plorations,astandardizedmealplancom-
prising 2,200  200 calories (35 cal/kg)
with 55  5% carbohydrate daily was
provided to the patients, distributed in
three meals and two snacks per day ad-
justed to body size and sex. Meals were
prepared by the same person for all sub-
jects and were identical in type, composi-
tion, recipe, and cooking method.
Prehemodialysis phase
The prehemodialysis phase started after
an 8-h overnight fast with initial anthro-
pometric measurements and resting elec-
trocardiogram and lasted at least 23 h.
Insulin was administered continuously
using an electric syringe pump, and cap-
illarybloodglucose,insulinﬂowrate,and
thepresenceofanysignsofhypoglycemia
were monitored every 1 h and every 30
min until 2 h postprandial.
Hemodialysis phase
Insulin infusion continued without inter-
ruption during the hemodialysis session.
It lasted for 4 h, with the following sys-
tematically recorded at the beginning and
at the end of hemodialysis session: time,
blood pressure and pulse rate, weight,
and body composition. Capillary blood
glucose and the insulin ﬂow rate were re-
corded every 30 min. Five milliliters of
venous blood were collected for the mea-
surement of blood urea nitrogen and se-
rum creatinine immediately before and
after the session.
Posthemodialysis phase
This phase lasted at least 23 h from the
end of the hemodialysis session, with fol-
low-up and intervention identical to the
prehemodialysis phase. A ﬁnal visit was
organized to conﬁrm the absence of
study-related adverse events 1 week after
discharge from hospital.
Measurements
Blood pressure was measured (in mmHg)
in the sitting position using an electronic
sphygmomanometer (Omron M5I), after
5minofrest.Weighttothenearest0.1kg
and body composition were measured by
impedancemetry and expressed as per-
cent body fat, body water, and lean body
mass (Tanita BC 418MA; Tanita, Tokyo,
Japan). Height was measured to the near-
est 0.5 cm in the erect position using a
wall stadiometer. BMI was calculated as
weightinkilogramsdividedbythesquare
of height in meters (kg/m
2). Waist cir-
cumference was measured to the nearest
centimeter at mid-level between the iliac
crest and lowest rib during expiration.
Insulin requirements
The24-heuglycemicclamp.Theinsulin
requirements were determined by main-
taining euglycemia by adjusting insulin
infusion rate to measured capillary glu-
cose using a 24-h euglycemic clamp in
near–free-living conditions. Brieﬂy, we
aimed to keep the blood glucose at 5.5 
1.1 mmol/l throughout the exploration.
The insulin infusion was set at a basal in-
sulin ﬂow rate of 0.3 IU/h, and a bolus
dose of 3 IU insulin was started 5 min
beforeeachmeal.Capillarybloodglucose
was measured just before every meal then
every 30 min for2hi nt h epostprandial
period then every 1 h during the rest of
the day and night using a Hemocue Glu-
cose 201 RT analyzer. The insulin ﬂow
rate was adjusted accordingly.
Blood urea nitrogen and serum creat-
inine were determined on venous blood
samplescollectedimmediatelybeforeand
at the end of the hemodialysis session us-
ing colorimetric methods. The quality of
dialysis was calculated as the logarithm of
the ratio of serum urea concentrations
at the beginning and at the end of
hemodialysis.
Adverse events
Expected adverse events were hypoglyce-
mia and local reaction at the site of infu-
sion,whichweremonitoredfor,aswellas
unpredictable events.
Ethics
The study was approved by the National
Ethical Committee of Cameroon.
Statistical analysis
The statistical analysis was done using
SPSS for Windows software version 15.0
(SPSS, Chicago, IL). Results were ex-
pressed as means  SD, unless otherwise
speciﬁed. Area under the curve was cal-
culated using the trapezoidal formula.
Comparisons between parameters were
performedbypairedttest.Spearmancor-
relation was used where necessary.
RESULTS
Study population
This study was carried out on 10 patients
undergoing two to three times weekly
maintenance hemodialysis, aged 55.7 
8.7 years (range 46.0–74.0) with known
durationofdiabetes11.94.5years,du-
rationofmaintenancehemodialysis2.3
2.3 years, mean BMI 22.7  4.5 kg/m
2,
andmeanwaistcircumference88.37.3
cm. Their mean total hemoglobin level
was 10.2  1.5 g/dl and A1C was 8.0 
1.2%.
Hemodialysis
Hemodialysisinducedadecrementincir-
culating blood urea nitrogen of 69.3 
15.5% (3.7  1.7 g/l before vs. 0.9  0.4
g/l after, P  0.0009) and 61.6  33.4
mg/l serum creatinine (85.6  36.6 mg/l
vs. 24.9  9.5 mg/l, P  0.0002). Esti-
matedbodywaterdecreasedfrom39.1
5.2 l to 34.7  4.2 l after hemodialysis
(P  0.0003).
Blood glucose variations
Over 52 h of investigation, participants
had an average of 64  2 determinations
of capillary glycemia each, with a mean
value of 5.3  0.8 mmol/l. The lowest
blood glucose levels recorded was 3.2
mmol/l prehemodialysis, 3.9 mmol/l per-
hemodialysis, and 3.7 mmol/l posthemo-
dialysis. All were asymptomatic. Overall
euglycemia was achieved throughout the
investigation with the area under the glu-
cosecurvepre-andposthemodialysisthat
were comparable (122.2 mmol prehemo-
dialysis vs. 121.8 mmol posthemodialy-
sis, P  NS).
Insulin requirements
Total insulin requirements and circa-
dian variations. On average, the 24-h
totaldoseofinsulinneededtoachieveeu-
glycemia was 23.6  7.7 IU prehemodi-
alysis vs. 19.9  4.9 IU posthemodialysis
(P  0.09). The circadian distribution of
theinsulinrequirementsprehemodialysis
was 28.0% from 0600 to 1200 h, 28.8%
from1200to1800h,29.7%from1800to
2400h, and 13.5% from 2400 to 0600 h
as shown in Table 1. The decrease in total
insulin requirements was more marked
for the 1200- to 1800-h period (Table 1).
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Basal insulin rate decreased by 25% post-
hemodialysis(0.1IU/h)comparedwith
prehemodialysis, while boluses did not
change signiﬁcantly as shown in Table
2.
Correlation with urea
There was no correlation between change
in urea and change in insulin require-
ments (Rs  0.10, P  0.78).
CONCLUSIONS — Using a 24-h eu-
glycemicclampinnear–free-livingcondi-
tions, this study has demonstrated a 15%
decrease in the daily insulin needs on the
dayafterhemodialysiscomparedwiththe
daily insulin needs before hemodialysis,
with a signiﬁcant reduction of basal
hourly insulin requirements by 25%, un-
changed boluses, and unchanged body
weight–indexed total insulin dose in a
groupoftype2diabeticpatientsonmain-
tenance hemodialysis.
The limited sample size is likely to
explain the marginal statistical signiﬁ-
cance of the difference in total insulin
dose variations. Despite this limitation,
because basal insulin requirements were
markedly and consistently reduced post-
hemodialysis, the difference appeared
clinically and statistically signiﬁcant. The
use of the intravenous route for insulin
administration in this investigation de-
servessomecautionforthegeneralization
to clinical situations where subcutaneous
routeisused.Validationintype1diabetic
patients would also be required. Because
each patient was his or her own control,
and because calorie intake and dialysis
procedure were standardized, the inﬂu-
ence of possible confounding determi-
nants of insulin requirements was
minimized.
Although the importance of intensive
blood glucose control on the progression
of renal disease has been demonstrated in
both type 1 (7) and type 2 (8) diabetes, it
is still unclear whether such an approach
would signiﬁcantly inﬂuence morbidity
and mortality in patients with ESRD (9–
12). Nevertheless, there is signiﬁcant
published evidence to indicate that such
patientsareathighriskoflife-threatening
glucose excursions and that the manage-
ment is cumbersome (9–12). However,
American Diabetes Association clinical
practice recommendations do not cur-
rently address the adjustment of insulin
therapy in diabetic patients with chronic
kidney disease undergoing hemodialysis
(13).
It is expected that hemodialysis,
mainly by clearing circulating urea,
wouldimproveinsulinsensitivityonboth
an acute and chronic basis (14). In fact,
DeFronzoetal.(15)haveshownthatafter
10 weeks of thrice-weekly hemodialysis
there is an improvement in insulin sensi-
tivity in uremic patients. In our study, al-
though we did not observe a signiﬁcant
correlation between the change in insulin
requirementsandchangeinurea,wecan-
not exclude the pathophysiological rela-
tion between improvement of insulin
sensitivity and the removal of blood urea
nitrogen, as previously reported (14,16).
Although insulin is poorly dialyzed,
greater insulin clearance on the dialysis
daymayalsoinﬂuencetheeffectivenessof
insulin on the postdialysis day. The insu-
lin requirements indexed to body weight
did not change signiﬁcantly, suggesting
that hemodialysis-induced body weight
changes are part of the mechanism.
In conclusion, we have shown in a
population with an average 2 years of
maintenancehemodialysisthatontheday
after hemodialysis, there is a signiﬁcant
25% decrease in basal insulin require-
ments of diabetic patients with ESRD, the
day posthemodialysis compared with the
day prehemodialysis for comparable food
consumption, but no signiﬁcant change
in bolus premeal insulin. These results
therefore support a systematic reduction
ofbasalexogenousinsulinadministration
by 25% in type 2 diabetic patients under-
going hemodialysis the day after dialysis.
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